BLOG

Durect hit? DNMT inhibitor may have found home in AH

With so many headlines touting drugs in development for the likes of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease, an illness in the same ballpark has been back-seated: alcoholic hepatitis (AH), which is on the rise, under-recognized and brings a one-month mortality rate that averages 26%.

Back to the Blog .st0{stroke:#000;stroke-width:3}.st0,.st1{fill:none}